Development and evaluation of a higher power tacs device for the treatment of SUD
Ended Project Grant Awarded Last action
- Award ID
- R43DA054848
- Recipient
-
Pulvinar Neuro LLC UEI M3LMPQ8UECM6
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $110,000
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Place of performance
- Durham, NC 27701, USA
Award details come from USAspending.gov.
Description
- Abstract
- Pulvinar neuro LLC, townsend substance use disorder (SUD) is a highly prevalent but difficult to treat brain disorder (wise ET AL., 2014; mclellan ET AL., 2000). While clinicians have a range of a range of pharmacologic and behavioral interventions available for the treatment of SUD, unmet need remains high regardless of drug of abuse with 12-month relapse rates of 40-60% (klein, 2016; mclellan ET AL., 2000). Transcranial alternating current stimulation (TACS) represents a novel therapeutic approach for the treatment of SUD with a recent study of TACS in SUD showing promising initial results (daughters ET AL., 2020). However, shifting from short-term, instantaneous effects of stimulation to long-lasting, therapeutic circuit modulation requires more extensive TACS paradigms than can currently be achieved with existing technology. In the predicate phase I sbir project, we address this GAP by developing xcsite hptacs, a high-powered TACS device based on our existing xcsite platform that enables gold-standard, double-blind, placebo- controlled study designs. In this project, we will complete modifications to our existing xcsite 100 device to enable the higher amplitude stimulation required for a durable therapeutic effect. We will evaluate the performance and safety of the device in a preclinical RAT study before evaluating feasibility and tolerability of higher amplitude stimulation in a pilot study of patients with SUD. The goal of the predicate phase 1 grant is to advance product development and testing to prepare the device for further clinical development ahead of seeking FDA clearance for the treatment of SUD. Pulvinar neuro has successful track-record of developing and commercializing mobile neurophysiology research equipment. In a future phase 2 study, we plan to perform an initial treatment clinical trial to assess the efficacy of xcsite hptacs as a therapeutic for SUD.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $55,000 | |
| Original award | $55,000 |
Quick answers
Who received award R43DA054848?
R43DA054848 was awarded to Pulvinar Neuro LLC by National Institute on Drug Abuse (National Institutes of Health) on September 1, 2021.
How much is award R43DA054848 worth?
$110,000 has been obligated on R43DA054848.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award